From partial physician buyouts to MSO acquisitions, understand every deal structure used in lower middle market ASC transactions — and how to negotiate terms that protect your interests.
Ambulatory surgery center acquisitions are among the most structurally complex transactions in the lower middle market. Unlike a typical business sale, ASC deals must navigate physician ownership regulations under the Stark Law and Anti-Kickback Statute, Medicare certification requirements, state Certificate of Need laws, and the critical need to retain the surgeon partners who drive case volume. A poorly structured deal can trigger regulatory violations, cause key physicians to walk, or leave sellers significantly undercompensated relative to true enterprise value. Most ASC transactions in the $1M–$5M revenue range trade at EBITDA multiples of 5x–9x, with valuation heavily influenced by payer mix quality, specialty diversification, accreditation status, and physician retention risk. Buyers range from private equity-backed ASC roll-up platforms and hospital systems to physician group management companies. Sellers are predominantly physician founders or multi-surgeon partnerships seeking liquidity events, recapitalizations, or succession solutions. The right deal structure aligns financial incentives, preserves clinical autonomy, satisfies regulatory requirements, and creates a clear path to post-close value creation for both parties.
Find Ambulatory Surgery Center Businesses For SalePartial Physician Equity Buyout with Rollover Ownership
The acquirer purchases a controlling interest — typically 51%–80% — of the ASC while surgeon partners retain a meaningful equity stake in the ongoing entity. Physicians roll a portion of their equity into the new ownership structure, maintaining both financial upside and clinical decision-making influence. This is the dominant deal structure in PE-backed ASC roll-up transactions.
Pros
Cons
Best for: PE-backed platforms executing multi-site ASC roll-ups seeking to retain high-volume surgeon partners and physician founders approaching retirement who want partial liquidity with continued upside
Management Services Organization (MSO) Acquisition
The acquirer purchases the non-clinical management and administrative assets of the ASC — including billing, staffing, real estate, and equipment — through an MSO entity, while physician partners retain ownership of the professional medical practice or clinical entity. This structure preserves the physician ownership model required under state corporate practice of medicine laws while giving the acquirer economic exposure to the business.
Pros
Cons
Best for: Non-physician strategic acquirers such as hospital systems or management companies entering states with strict corporate practice of medicine laws, or situations where physicians insist on retaining the clinical entity
Full Asset or Stock Acquisition
The acquirer purchases 100% of the ASC — either as an asset purchase or stock acquisition — with the previous physician owners fully exiting ownership. Asset purchases are more common due to the ability to step up the tax basis on equipment and avoid assumption of unknown liabilities, while stock acquisitions may be preferred when transferring Medicare provider agreements and payer contracts that are non-assignable.
Pros
Cons
Best for: Retirement-minded physician founders seeking complete liquidity, single-physician ASC owners without succession plans, or multi-specialty centers where volume is distributed across a broad and stable physician panel not dependent on any one seller
Earnout Structure Tied to Case Volume and Payer Contract Milestones
A portion of the total purchase price — typically 10%–25% — is deferred and paid contingent on post-close performance milestones, most commonly case volume growth targets, successful payer contract renegotiation at improved rates, or retention of key surgeon partners through a defined window. Earnouts are frequently layered onto partial or full acquisition structures rather than used as standalone deal types.
Pros
Cons
Best for: Transactions where projected case volume growth or payer rate improvements are central to the buyer's valuation thesis but cannot be confirmed at closing, or where a valuation gap exists between buyer and seller expectations
PE Roll-Up Platform Acquires Orthopedic ASC with Physician Rollover
$8.5 million (7.1x EBITDA on $1.2M trailing EBITDA)
$6.8M (80%) paid in cash at close to three orthopedic surgeon partners; $1.7M (20%) rolled into equity in the PE platform's ASC holdco entity at equivalent valuation
Seller physicians retain 22% combined equity in the platform entity with pro-rata tag-along rights on any future exit. Three-year employment or medical director agreements with market-rate compensation executed simultaneously. No earnout. PE platform funds acquisition with 50% senior debt from a healthcare-focused lender and 50% equity from its fund.
Hospital System MSO Acquisition of Multi-Specialty ASC
$5.2 million for MSO assets (equipment, real estate lease assignment, billing operations, staff employment contracts)
$5.2M paid fully in cash at close for all non-clinical management assets. Physician partnership retains 100% ownership of the professional entity and continues clinical operations under a 10-year management services agreement with the hospital system's MSO subsidiary.
MSO management fee set at 12% of net patient revenue, validated by a third-party fair market value opinion. Physicians retain full clinical governance, scheduling authority, and payer contracting input through a joint operating committee. Hospital system receives right of first refusal on the physician entity if partners elect to sell the professional entity within 7 years.
Full Asset Sale — Retiring GI Physician Selling Single-Specialty ASC
$3.1 million (6.2x EBITDA on $500K trailing EBITDA)
$2.6M (84%) paid at close. $500K (16%) held in escrow for 18 months tied to two earnout milestones: $250K upon successful Medicare re-enrollment and payer contract assignment within 90 days, and $250K if case volume in months 7–18 post-close meets or exceeds 90% of the trailing 12-month baseline.
Seller provides a 6-month transition services agreement at $8,000/month to support credentialing, payer re-contracting, and referral source introductions. Asset purchase structure used to allow buyer to step up equipment basis. Seller provides 3-year non-compete within 25-mile radius.
Find Ambulatory Surgery Center Businesses For Sale
Pre-screened targets ready for your deal structure — free to join.
Lower middle market ASCs with $1M–$5M in revenue typically trade at 5x–9x EBITDA, with the wide range reflecting significant variation in quality factors. Centers at the higher end of the multiple range share common characteristics: EBITDA margins of 25% or above, diversified multi-specialty case mix, strong Medicare and commercial payer contracts with locked-in rates, AAAHC or Joint Commission accreditation, and a physician panel where no single surgeon represents more than 30% of case volume. Centers facing reimbursement concentration risk, aging equipment, or heavy Medicaid volume will trade closer to the 5x–6x range. PE platforms executing roll-up strategies may pay premium multiples of 8x–9x for well-positioned centers that fit their geographic expansion thesis.
No. Ambulatory surgery centers are not eligible for SBA 7(a) or SBA 504 loan programs due to their classification as healthcare facilities with Medicare and Medicaid revenue streams, which are excluded under SBA rules for businesses deriving revenue from government reimbursement programs. ASC acquisitions are typically financed through conventional senior debt from healthcare-focused commercial lenders, PE fund equity, or seller financing structured as subordinated notes. Buyers should engage lenders with specific healthcare M&A experience, as standard commercial banks often lack the underwriting expertise to properly evaluate ASC cash flow quality.
Federal Stark Law and Anti-Kickback Statute requirements are central to every ASC deal structure. Under the Stark Law whole entity exception, physician investors in an ASC may receive returns on their ownership interest — but the investment terms must reflect fair market value, all investors must be properly disclosed, and no investment returns can be tied to referral volume. Deals where the buyer is a hospital system require additional scrutiny, as hospital-physician financial relationships face heightened Stark Law enforcement. Any ongoing compensation paid to physicians post-acquisition — management fees, medical director stipends, compensation arrangements — must be documented with a third-party fair market value opinion. Engaging specialized healthcare M&A counsel is not optional; it is essential.
The answer depends critically on whether the transaction is structured as an asset purchase or a stock acquisition. In a stock acquisition, existing payer contracts typically remain in place because the legal entity holding those contracts has not changed — only ownership of that entity has transferred. In an asset purchase, payer contracts must generally be assigned or novated to the acquiring entity, which requires advance notification to and consent from each payer. Most commercial payer contracts contain change-of-control provisions that trigger renegotiation rights. Buyers should conduct a detailed payer contract review during diligence and initiate payer notification processes early to avoid revenue disruption. Medicare enrollment in a new entity following an asset purchase requires formal re-enrollment and can take 60–180 days.
Achieving internal consensus is one of the most important — and most often underestimated — pre-sale steps for physician partnerships. Before engaging buyers or advisors, all physician partners should formally agree on the allocation of sale proceeds relative to their ownership percentages, which partners will roll equity versus take full liquidity, governance rights post-close, and the minimum acceptable deal terms. Disagreement discovered during buyer diligence signals execution risk and materially weakens negotiating leverage. Engaging an experienced healthcare M&A advisor early can help facilitate the internal consensus process and ensure partnership agreements, buy-sell provisions, and consent requirements are properly documented before the marketing process begins.
From signed letter of intent to closing, ASC acquisitions in the lower middle market typically require 90–180 days, with the wide range driven by regulatory complexity. The most time-consuming elements are healthcare-specific: payer contract assignment or renegotiation, state licensure transfer filings, Medicare enrollment processing, CON compliance review in applicable states, and accreditation body notification requirements. Transactions involving hospital system buyers or PE platforms with existing provider agreements may move faster due to institutional familiarity with regulatory workflows. Sellers should plan for the full 180-day window and ensure their compliance documentation, licensure files, and data room are fully organized before LOI execution to avoid diligence delays that extend timelines and create deal fatigue.
More Ambulatory Surgery Center Guides
More Deal Structure Guides
Find the right target, structure the deal, and close with confidence.
Create your free accountNo credit card required
For Buyers
For Sellers